---
document_datetime: 2026-01-28 14:24:49
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/koselugo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: koselugo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.2465066
conversion_datetime: 2026-01-29 12:02:05.105895
docling_version:
  docling-serve: 1.11.0
  docling-jobkit: 1.9.0
  docling: 2.70.0
  docling-core: 2.61.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Koselugo

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                            |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------|
| Variation type II /  | C.I.6 Change(s) to therapeutic indication(s) | 18/09/2025                          | 24/10/2025                                  | SmPC and PL                      | Please refer to Scientific Discussion Koselugo-II- |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000245231          | - C.I.6.a Addition of a new therapeutic indication or modification of an approved one - Accepted Extension of indication for KOSELUGO to include treatment of adults based on results from study D134BC00001 (KOMET). This is a phase III, multicentre, international study with a parallel, randomised, double-blind, placebo-controlled, 2 arm design that assesses efficacy and safety of selumetinib in adult participants with NF1 who have Symptomatic Inoperable Plexiform Neurofibromas. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.1 of the RMP has also been agreed. In addition, the Marketing authorisation holder (MAH) took the opportunity to implement editorial changes   | EMAVR0000245231-AR-en.   |
|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| PSUR / EMA/PSUR/0000282270 | - -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Maintenance              |